Solve Therapeutics vs Modal

Side-by-side comparison of AI visibility scores, market position, and capabilities

Modal leads in AI visibility (45 vs 28)
Solve Therapeutics logo

Solve Therapeutics

EmergingBioTech

Antibody-Drug Conjugates (Solid Tumors)

Raised $120M oversubscribed (Nov 2025) with Merck & Co. as new equity investor. $321M total. CloakLink ADC technology reduces hydrophobicity and toxicity. Two Phase 1b solid tumor trials active.

AI VisibilityBeta
Overall Score
D28
Category Rank
#1 of 1
AI Consensus
60%
Trend
up
Per Platform
ChatGPT
37
Perplexity
33
Gemini
34

About

Solve Therapeutics develops antibody-drug conjugates (ADCs) using its proprietary CloakLink technology — which reduces the hydrophobicity and systemic toxicity that are the two primary causes of ADC clinical failure. The company raised $120 million in an oversubscribed financing round in November 2025, with Merck & Co. making a direct equity investment (rather than a typical licensing deal), bringing total funding to $321 million. Two ADC programs (SLV-154 and SLV-324) are in active Phase 1b trials in solid tumor patients.

Full profile
Modal logo

Modal

EmergingAI & Machine Learning

Serverless ML

Serverless GPU cloud platform for AI/ML with Python-native deployment and per-second billing; developer-favorite scaling from zero competing with Replicate and Beam for AI compute.

AI VisibilityBeta
Overall Score
C45
Category Rank
#1 of 1
AI Consensus
55%
Trend
up
Per Platform
ChatGPT
38
Perplexity
50
Gemini
53

About

Modal is a serverless cloud computing platform purpose-built for AI and machine learning workloads — providing on-demand GPU compute that scales instantly from zero with per-second billing, container management, distributed training support, and a Python-native developer experience that makes running ML workloads in the cloud feel as simple as running code locally. Founded in 2021 in New York City and backed by Redpoint Ventures and other investors, Modal has grown rapidly as AI development has accelerated demand for flexible, developer-friendly GPU infrastructure.\n\nModal's developer experience is its primary differentiator — engineers write Python functions decorated with @modal.function() and deploy them to the cloud with a single command, with Modal handling container building, GPU provisioning, auto-scaling, and execution. The platform supports training jobs that need distributed compute across multiple GPUs, model serving endpoints that scale to zero when unused (eliminating idle GPU costs), and batch inference jobs that process large datasets. The per-second billing model means developers pay only for actual compute time, not provisioned instances.\n\nIn 2025, Modal competes in the AI infrastructure market with Replicate, Beam, Banana, and major cloud providers' managed ML services (AWS SageMaker, Google Vertex AI, Azure ML) for serverless GPU compute. The market for AI-specific cloud infrastructure has grown dramatically as the number of ML engineers deploying models to production has expanded — traditional cloud providers require significant DevOps expertise to use GPU instances effectively, while Modal's Python-native approach reduces the barrier to entry. Modal has attracted a strong developer following among AI researchers and ML engineers building production AI applications. The 2025 strategy focuses on growing the developer community, adding enterprise features (dedicated GPU capacity, private networking, compliance), and expanding the hardware options available (H100 GPUs, custom accelerators).

Full profile

AI Visibility Head-to-Head

28
Overall Score
45
#1
Category Rank
#1
60
AI Consensus
55
up
Trend
up
37
ChatGPT
38
33
Perplexity
50
34
Gemini
53
24
Claude
39
22
Grok
37

Capabilities & Ecosystem

Capabilities

Only Solve Therapeutics
Antibody-Drug Conjugates (Solid Tumors)
Only Modal
Serverless ML

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.